Analysts Set CRISPR Therapeutics AG (NASDAQ:CRSP) PT at $77.93

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have earned an average rating of “Hold” from the eighteen research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $77.93.

CRSP has been the topic of several research reports. Needham & Company LLC reiterated a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Royal Bank of Canada restated a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. JMP Securities reiterated a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Chardan Capital restated a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Finally, Barclays lowered their price target on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th.

Insider Activity

In related news, CEO Samarth Kulkarni sold 4,293 shares of the stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. This trade represents a 1.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at $2,896,989.16. This represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,382 shares of company stock worth $2,744,179 over the last ninety days. Company insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Large investors have recently added to or reduced their stakes in the company. Larson Financial Group LLC boosted its stake in shares of CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after purchasing an additional 276 shares in the last quarter. Itau Unibanco Holding S.A. bought a new stake in CRISPR Therapeutics during the 2nd quarter valued at approximately $35,000. Wilmington Savings Fund Society FSB purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $40,000. Darwin Wealth Management LLC bought a new position in shares of CRISPR Therapeutics in the 3rd quarter worth approximately $43,000. Finally, Denver PWM LLC purchased a new position in shares of CRISPR Therapeutics in the 2nd quarter valued at approximately $45,000. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $38.65 on Friday. The company’s fifty day moving average price is $47.48 and its two-hundred day moving average price is $49.76. The firm has a market capitalization of $3.30 billion, a PE ratio of -13.66 and a beta of 1.62. CRISPR Therapeutics has a 52-week low of $38.20 and a 52-week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period in the previous year, the business earned ($1.41) earnings per share. Analysts predict that CRISPR Therapeutics will post -5.13 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.